Factors affecting survival in patients with the acquired immunodeficiency syndrome

AIDS

Volumn 10, Issue 10, 1996, Pages 1057-1065

  Mocroft, Amanda ^a   Johnson, Margaret A ^a   Phillips, Andrew N ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

AIDS; AIDS defining illness; CD4 count; Demographic factors; Survival; Treatment

Indexed keywords

CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; DEMOGRAPHY; HUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL; T LYMPHOCYTE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BIOLOGY; CASE FATALITY RATE; DEATH RATE; DEMOGRAPHIC FACTORS; DISEASES; HIV INFECTIONS; IMMUNITY; IMMUNOLOGIC FACTORS; INFECTIONS; MORTALITY; PHYSIOLOGY; POPULATION; POPULATION DYNAMICS; RISK FACTORS; TIME FACTORS; TREATMENT; VIRAL DISEASES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; HUMANS; QUALITY OF LIFE; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0029789255     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (168)

1. Center for Disease Control: Pneumocystis carinii pneumonia - Los Angeles. MMWR 1981, 30:250-252.
2. Center for Disease Control: Kaposi's sarcoma and Pneumocystis carinii pneumonia among homosexual men - New York City and California. MMWR 1981, 30:305-308.
3. Gottlieb MS, Schroff R, Schanker HM, et al.: Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men : Evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981, 305:1425-1431.
4. Hymes KB, Cheung T, Greene JB, et al.: Kaposi's sarcoma in homosexual men - a report of eight cases. Lancet 1981, ii:598-600.
5. World Health Organization: WHO AIDS data at 31 December 1994 and the current global situation of the HIV/AIDS pandemic. Wkly Epidemiol Rec 1995, 70:5-8.
6. Global Programme on AIDS: Current and future dimensions of the HIV/AIDS pandemic: a capsule summary. Geneva: WHO April 1991.
7. Fleming AF: Opportunistic infections in AIDS in developed and developing countries. Trans Roy Soc Trop Med Hyg 1990, 84 (suppl 1):S1-S6.
8. Beck EJ, Whitaker L, Kennelly J, et al.: Changing presentation and survival, service utilization and costs for AIDS patients:insights from a London referral centre. AIDS 1994, 8:379-384.
9. Kennelly JM, Tolley KH, Ghani ACH, Sabin CA, Meynard AK, Lee CA: Hospital costs of treating haemophiliac patients infected with HIV. AIDS 1995, 9:787-793.
10. Piette JD, Intrator O, Zierler S, Mor V, Stein MD: An exploratory analysis of survival with AIDS using a non parametric tree-structured approach. Epidemiology 1992, 3:310-318.
11. Blum S, Singh TP, Gibbons J, et al.: Trends in survival among persons with acquired immunodeficiency syndrome in New York City. The experience of the first decade of the epidemic. Am J Epidemiol 1994, 139:351-361.
12. Piette J, Mor V, Fleishman J: Patterns of survival with AIDS in the United States. Health Serv Research 1991, 26:75-95.
13. Lundgren JD, Pedersen C, Clumeck N, et al.: Survival differences in patients with AIDS, 1979-1989. BMJ 1994, 308:1068-1073.
14. Rothenberg R, Woelfel M, Stoneburner R, Milberg J, Parker R, Truman B: Survival with the acquired immunodeficiency syndrome - experience with 5833 cases in New York city. N Engl J Med 1987, 317:1297-1302.
15. Lemp GF, Payne S F, Neal D, Temelso T, Rutherford GW: Survival trends for patients with AIDS. JAMA 1990, 263:402-406.
16. Whitmore-Overton SE, Tillet HE, Evans BG, Allardice GM: Improved survival from diagnosis of AIDS in adult cases in the United Kingdom and bias due to reporting delays. AIDS 1993, 7:415-420.
17. Chang HH, Morse DL, Noonan C, et al.: Survival and mortality patterns of an acquired immunodeficiency syndrome (AIDS) cohort in New-York state. Am J Epidemiol 1993, 138:341-349.
18. Luo K, Law M, Kaldor JM, McDonald AM, Cooper DA: The role of initial AIDS-defining illness in survival following AIDS. AIDS 1995, 9:57-63.
19. Chequer P, Herst N, Hudes ES, et al.: Determinants of survival in adult Brazilian AIDS patients, 1982-1989. AIDS 1992, 6:483-487.
20. Seage GR III, Oddleifson S, Carr E, et al.: Survival with AIDS in Massachusetts 1979-1989. Am J Public Health 1993, 83:72-78.
21. Payne SF, Lemp GF, Rutherford GW: Survival following diagnosis of Kaposi's sarcoma for AIDS patients in San Francisco. J Acquir Immune Defic Syndr 1990, 3 (suppl 1):S14-S17.
22. Jacobson LP, Kirby AJ, Polk S, et al.: Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984-1991. Am J Epidemiol 1993, 138:952-964.
23. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A: Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983-1993. JAMA 1994, 271:1083-1087.
24. Stehr-Green JK, Holman RC, Mahoney MA: Survival analysis of hemophilia-associated AIDS cases in the US. Am J Public Health 1989, 79:832-835.
25. Reeves GK, Overton SE. Preliminary survival analysis of UK AIDS data [letter]. Lancet 1988, i:880.
26. Buira E, Gatell JM, Miro JM, et al.: Influence of treatment with zidovudine (ZDV) on the long-term survival of AIDS patients. J Acquir Immune Defic Syndr 1992, 5:737-742.
27. Whyte BM, Swanson CE, Cooper DA: Survival of patients with the acquired immunodeficiency syndrome in Australia. Med J Aust 1989, 150:358-362.
28. d'Arminio Monforte A, Mainini F, Bini T, et al.: Survival differences for 547 AIDS cases in Milan [letter]. J Acquit Immune Defic Syndr 1992, 5:1276-1277.
29. Friedland GH, Saltzman B, Vileno J, Freeman K, Schrager LK, Klein RS: Survival differences in patients with AIDS. J Acquir Immune Defic Syndr 1991, 4:144-153.
30. Bacchetti P, Osmond D, Chaisson RE, et al.: Survival patterns of the first 500 patients with AIDS in San Francisco. J Infect Dis 1988, 157:1044-1047.
31. Bindels PJ, Poos RMJ, Jong JT, Mulder JW, Jager HJC, Coutinho RA: Trends in mortality among AIDS patients in Amsterdam, 1982-1988. AIDS 1991, 5:853-858.
32. Kitayaporn D, Tansuphaswadikul S, Lohsomboon P, et al.: Survival of AIDS patients in the emerging epidemic in Bangkok, Thailand. J Acquir Immune Defic Syndr 1996, 11:77-82.
33. Pedersen C, Gerstoft J, Tauris P, et al.: Trends in survival of Danish AIDS patients from 1981 to 1989. AIDS 1990, 4:1111-1116.
34. Greco D, Stazi MA, Rezza G: Length of survival of patients with AIDS [letter]. BMJ 1986, 293:451-452.
35. Swanson CE, Tindall B, Cooper DA, for the Australian Zidovudine Study Group: Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: factors influencing development of AIDS, survival and drug intolerance. AIDS 1994, 8:625-634.
36. Carlson MV, Skegg DCG, Paul C, Spears GFS: Occurrence of AIDS in New Zealand: the first seven years. NZ Med J 1991, 104:131-134.
37. Ghirardini A, Puopolo M, Rossetti G, et al.: Survival after AIDS among Italian haemophiliacs with HIV infection. AIDS 1995, 9:1351-1356.
38. Marasca G, McEvey M: Length of survival of patients with acquired immune deficiency syndrome in the United Kingdom. BMJ 1986, 292:1727-1729.
39. Eskild A, Magnus P, Nilsen O, Hasseltvedt V, Lystad A: Asymptomatic subjects at HIV diagnosis have prolonged survival as AIDS patients. Int J Epidemiol 1992, 21:387-390.
40. Bindels PJ, Krol A, Roos M, et al.: The predictive value of T cell function in vitro and pre-AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam. J Infect Dis 1995, 172:97-104.
41. Eskild A, Magnus P, Nilsen O, Holme I: Survival of AIDS patients in Norway. Scand J Soc Med 1990, 18:231-235.
42. Low N, Paine K, Clark R, Mahalingam M, Pozniak AL: AIDS survival and progression in black Africans living in South London, 1986-1994. Genitourin Med 1996, 72:12-16.
43. Harris JE: Improved short term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia 1984 through 1987. JAMA 1990, 263:397-401.
44. Saah AJ, Hoover DR, He Y, Kingsley LA, Phair JP: Factors influencing survival after AIDS: report from the Multicentre AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1994, 7:287-295.
45. Bulterys M, Nzabihimana E, Chao A, et al.: Long term survival among HIV-1-infected prostitutes [letter]. AIDS 1993, 7:1269.
46. Phillips AN, Lee CA, Elford J, et al.: More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J Acquir Immune Defic Syndr 1991, 4:970-975.
47. Eyster ME, Gail MH, Ballard JO, Al-Mondhiry H, Goedert JJ: Natural history of human immunodeficiency virus infection in haemophiliacs: effects of T-cell subsets, platelet counts and age. Ann Intern Med 1987, 107:1-6.
48. Darby SC, Ewart DW, Giangrande PLF, et al.: Mortality before and after HIV infection in the complete UK population of haemophiliacs. Nature 1995, 377:79-82.
49. Mackall CL, Fleisher TA, Brown MR, et al.: Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995, 332:143-149.
50. Ben-Yehuda A, Weksler ME: Immune senescence : mechansims and clinical implications. Cancer Invest 1992, 10:525-531.
51. Ferro S, Salit IE: HIV infections in patients over 55 years of age. J Acquir Immune Defic Synd 1992, 5:348-353.
52. Moore RD, Hidalgo J, Sugland BW, Chaisson RE: Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991, 324:1412-1416.
53. Easterbrook PJ, Keruly JC, Creagh-Kirk T, Richman DD, Chaisson RE, Moore RD: Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. JAMA 1991, 266:2713-2718.
54. Sha BE, Benson CA, Pottage JC Jr, Urbanski PA, Daugherty SR, Kessler HA: HIV-infection in women observational study of clinical characteristics, disease progression, and survival for a cohort of women in Chicago. J Acquire Immune Defic Synd 1995, 8:486-495.
55. Whittle H, Egboga A, Todd J, et al.: Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection. AIDS 1992, 6:685-689.
56. Lucas SB, Hounnou A, Peacock C, et al.: The mortality and pathology of HIV infection in a West African City. AIDS 1993, 7:1569-1579.
57. Egger M, Twisselmann W, Ledergerber B, et al.: Differences in progression of HIV infection between men and women [letter]. BMJ 1995, 310:941.
58. Iatrakis CM, Shah PN, Smith JR, Kitchen VS, Barton S: Survival of men and women with AIDS : a comparative study [letter]. Genitourin Med 1994, 70:290.
59. Phillips AN, Antunes F, Stergious G, et al.: A sex comparison of rates of new AIDS-defining diseases and death in 2554 AIDS cases. AIDS 1994, 8:831-835.
60. Cozzi-Lepri A, Pezzotti P, Dorrucci M, Phillips AN, Rezza G: HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. BMJ 1994, 309:1537-1542.
61. Chaisson RE, Keruly JC, Moore RD: Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995, 333:751-756.
62. Vella S, Giuliano M, Floridia M, et al.: Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients. AIDS 1995, 9:51-56.
63. Fleming PL, Ciesielski CA, Byers RH, Castro KC, Berkelman RL: Gender differences in reported AIDS-indicative diagnoses. J Infect Dis 1993, 168:61-67.
64. Rich KC, Siegel JN, Jennings C, et al.: CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy induced immune depression in uninfected and HIV-infected women. J Infect Dis 1995, 172:1221-1227.
65. Carpenter CC, Mayer KH, Stein MD, Leibman BD, Fisher A, Fiore T: Human immunodeficiency virus infections in North American women: experience with 200 cases and a review of the literature. Medicine 1991, 70:307-325.
66. Stein M, Pieete J, Mor V, et al.: Differences in access to zidovudine (AZT) among asymptomatic HIV-infected persons. J Gen Intern Med 1991, 6:35-40.
67. Beral V: Epidemiology of Kaposi's sarcoma. Cancer Surv 1991, 10:5-22.
68. Hanson DL, Chu SY, Farizio KM, Ward JW: Distribution of CD4+ T-lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus related illnesses. Arch Intern Med 1995, 155:1537-1542.
69. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF: Predictive value of CD4 lymphocyte numbers for the development ofopportunistic infections and malignancies in HIV-infected persons. J Acquire Immun Defic Synd 1991, 4:770-776.
70. Selwyn PA, Hartel D, Wasserman W, Drucker E: Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance programme. Am J Public Health 1989, 79:1358-1362.
71. Alcabes P, Schoenbaum EE, Klein RS: Correlates of the rate of decline of CD4+ lymphocytes among injection drug users infected with the human immunodeficiency virus. Am J Epidemiol 1993, 137:989-1000.
72. Hogg RS, Strathdee SA, Craib KJP, Shaugnessy MVO, Montaner JSG, Schlechter MT: Lower socioeconomic status and shorter survival following HIV infection. Lancet 1994, 344:1120-1124.
73. Apolonio EG, Hoover DR, He Y, et al.: Prognostic factors in human immunodeficiency virus -positive patients with a CD4+ lymphocyte count < 50/μl. J Infect Dis 1995, 171:829-836.
74. Veugelers PJ, Page KA, Tindall B , et al.: Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol 1994, 140:747-758.
75. Lyketsos CC, Hoover DR, Guccione M, et al.: Depressive symptoms as predictors of medical outcomes in HIV infection. JAMA 1993, 270:2563-2567.
76. Taylor JMG, Sy JP, Visscher B, Giorgi JV: CD4+ cell number at the time of acquired immunodeficiency syndrome. Am J Epidemiol 1995, 141:645-651.
77. Schwartländer B, Horsburgh CR Jr, Hamouda O, Skarabis H, Koch MA: Changes in the spectrum of AIDS-defining conditions and decrease in CD4+ lymphocyte counts at AIDS manifestation in Germany from 1986 to 1991. AIDS 1992, 6:413-420.
78. Alcabes P, Selwyn PA, Davenny K, et al.: Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. AIDS 1994, 8:107-115.
79. Phillips AN, Pezzotti P, Lepri AC, Rezza G, Italian Seroconversion Study: CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from the Italian Seroconversion Study. AIDS 1994, 8:1299-1305.
80. Mills CD, Jones PD: Relationship between CD4 lymphocyte count and AIDS mortality, 1986-1991. AIDS 1993, 7:1383-1386.
81. Yarchoan R, Venzon DJ, Pluda JM, et al.: CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med 1991, 115:184-189.
82. Brinchman JE, Vartdal F, Thorsby E: T lymphocyte subset changes in human immunodeficiency virus infection. J Acquir Immune Defic Syndr 1989, 2:398-405.
83. Phillips AN, Elford J, Sabin C, Bofill M, Janossy G, Lee CA: Immunodeficiency and the risk of death in HIV infection. JAMA 1992, 268:2662-2666.
84. Moore RD, Keruly J, Richman DD, Creagh-Kirk T, Chaisson RE, Zidovudine Epidemiology Study Group: Natural history of advanced HIV disease in patients treated with zidovudine. AIDS 1992, 6:671-677.
85. Hanson DL, Horsburgh CR Jr, Fann SA, Havlik JA, Thompson SE III: Survival prognosis of HIV-1 infected patients. J Acquir Immune Defic Syndr 1993, 6:624-629.
86. Colford JM Jr, Ngo L, Taer I: Factors associated with survival in human immunodeficiency virus infected patients with very low CD4 counts. Am J Epidemiol 1994, 139:206-218.
87. Durant J, Bernard E, Benhamou P, et al.: Analysis of survival in 281 patients with AIDS in southern France [letter]. J Infect Dis 1991, 164:1028-1029.
88. Stoneburner R, Laroche E, Prevots R, et al.: Survival in a cohort of human immunodeficiency virus infected tuberculosis patients in New York City. Implications for expansion of the AIDS case definition. Arch Intern Med 1992, 152:2033-2037.
89. Korzeniewska-Kosela M, Fitzgerald JM, Vedal S, et al.: Spectrum of tuberculosis in patients with HIV infection in British Columbia; report of 40 cases. Can Med Assoc Journal 1992, 146:1927-1934.
90. Fiala M, Kermani V, Gornbein J: Role of CD8+ in late opportunistic infections of patients with AIDS. Res Immunol 1992, 143:903-907.
91. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R: Risk of developing cytomegalovirus retinitis in persons with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992, 5:1069-1074.
92. d'Arminio Monforte A, Mainini F, Vago L, et al.: Factors associated with increased risk of acquiring cytomegalovirus disease in AIDS patients [letter]. J Infect Dis 1993, 168:1071-1072.
93. Chin DP, Reingold AL, Stone EN, et al.: The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients. A prospective study. J Infect Dis 1994, 170:578-584.
94. Horsburgh CR Jr, Metchock B, Gordon SM, Havlik JA Jr, McGowan JE Jr, Thompson SE III: Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease. J Infect Dis 1994, 170:573-577.
95. Turner BJ, Markson LE, McKee L, Houchens R, Fanning T: The AIDS-defining diagnosis and subsequent complications: a survival based severity index. J Acquire Immun Defic Synd 1991, 4:1059-1071.
96. Gallant JE, Moore RD, Chaisson RE: Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994, 120:932-944.
97. Pitchenik AE, Fertel D: Medical management of AIDS patients. Tuberculosis and non tuberculosis mycobacterium disease. Med Clin North Am 1992, 76:121-171.
98. Pneumocystis pneumonia therapy project group, Haverkos KW: Assessment of therapy for Pneumocystis carinii pneumonia. Am J Med 1984, 100:663-671.
99. Dohn MN, Baughman RP, Vigdorth EM, Frame DL: Equal survival rates for first, second and third episodes of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Arch Intern Med 1992, 152:2465-2470.
100. Maden C, Hopkins SG, Smyser M, Lafferty WE: Survival after AIDS diagnosis in Washington state: trends through 1989 and the effect of the case definition change of 1987. J Acquir Immune Defic Syndr 1994, 6:1157-1161.
101. McGowan I, Hawkins AS, Weller IVD: The natural history of cryptosporidial diarrhoea in HIV-infected patients. AIDS 1995, 7:449-454.
102. Flanigan T, Whalen C, Turner J, et al.: Cryptosporidial infection and CD4 counts. Ann Intern Med 1992, 116:840-842.
103. Wenger JD, Whalen CC, Lederman MM, et al.: Prognostic factors in acquired immunodeficiency syndrome. J Gen Int Med 1988 3:464-470.
104. Mocroft AJ, Johnson MA, Sabin CA, et al.: Clinical staging system for AIDS patients. Lancet 1995, 346:12-17.
105. van der Ven AJ, Koopmans PP, Vree TH, van der Meer JW: Drug intolerance in HIV disease. J Antimicrob Chemother 1994, 34:1-5.
106. Rooney MD: Guide to medications used to treat acquired immune deficiency syndrome. J Am Podiatr Med Ass 1995, 85:375-393.
107. Blumenfield M, Milazzo J, Wormser GP: Non-compliance in hospitalised patients with AIDS. Gen Hosp Psy 1990, 12:166-169.
108. Centers for Disease Control: Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. Ann Intern Med 1986, 105:234-237.
109. Redfield RR, Wright DC, Tramont EC: The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med 1986, 314:141-142.
110. Royce RA, Luckmann RS, Fusaro KE, Winkelstein W Jr: The natural history of HIV-1 infection: staging classification of disease. AIDS 1991, 5:355-364.
111. Montaner JSG, Le TN, Le N, Craib KJP, Schechter MT: Application of the World Health Organization system for HIV infection in a cohort of homosexual men in developing a prognostically meaningful staging system. AIDS 1992, 6:719-724.
112. The WHO International Collaboration Group for the Study of the WHO Staging System: Proposed 'World Health Organization Staging System for HIV Infection and Disease': preliminary testing by an international collaborative cross-sectional study. AIDS 1993, 7:711-718.
113. Rabeneck L, Wray NP: Predicting the outcome of human immunodeficiency virus infection. How well are we doing? Arch Intern Med 1993, 153:2749-2755.
114. Neaton JD, Wentworth DN, Rhame F, Hogan DI, Deyton L: Considerations in choice of a clinical endpoint for AIDS clinical trials. Stats in Med 1994, 13:2107-2125.
115. Justice AC, Feinstein AR, Wells CK: A new prognostic staging system for the acquired immunodeficiency syndrome. N Engl J Med 1989, 320:1388-1393.
116. Cozzi Lepri A, Pezzotti P, Phillips AN, Petrutcci A, Rezza GI: Clinical staging system for AIDS patients [letter]. Lancet 1995, 346:1103.
117. Poznansky MC, Coker R, Skinner C, et al.: HIV positive patients first presenting with an AIDS defining illness: characteristics and survival. BMJ 1995, 311:156-158.
118. Reed GM, Kemeny ME, Taylor SE, Wang HY, Visscher BR: Realistic acceptance as a predictor of decreased survival time in gay men with AIDS. Health Psychology 1994, 13:299-307.
119. Laraque F, Greene A, Triano-Davis JW, et al.: Effect of comprehensive intervention program on survival of patients with human immunodeficiency virus infection. Arch Intern Med 1996, 156:169-176.
120. Wright TL, Hollander H, Pu X, et al.: Hepatitis C in HIV-infected patients with and without AIDS : prevalence and relationship to patient survival. Hepatology 1994, 20:1152-1155.
121. Diamondstone LS, Blakely SA, Rice JC, et al.: Prognostic factors for all cause mortality among haemophiliacs infected with human immunodeficiency virus. Am J Epidemiol 1995, 142:304-313.
122. Scharschmidt BF, Held MJ, Hollander HH, et al.: Hepatitis B in patients with HIV infection : relationship to AIDS and patient survival. Ann Intern Med 1992, 117:837-838.
123. Tovo PA, de Martino M, Gabiano C, et al.: Prognostic factors and survival in children with perinatal HIV-1 infection. Lancet 1992, 339:1249-1253.
124. 2-microglobulin, and hepatitis B surface antigenemia with death in infants and children with HIV-1 disease. J Acquir Immune Optic Syndr 1994, 7:1079-1085.
125. Drew WL, Mintz L, Miner RC, et al.: Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis 1981, 143:188-192.
126. Mintz L, Drew WL, Miner RC, Braff EH: Cytomegalovirus infections in homosexual men: an epidemiological study. Ann Intern Med 1983, 98:326-329.
127. Sabin CA, Phillips AN, Lee CA, Janossy G, Emery V, Griffiths PD: The effect of CMV infection on progression of human immunodeficiency virus diseases in a cohort of haemophilic men followed for up to 13 years from seroconversion. Epidemiol Infect 1995, 114:361-372.
128. Furman PA, Fyfe JA, St Clair MH, et al.: Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986, 83:8333-8337.
129. Fischl MA, Richman DD, Grieco MH, et al.: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double blind, placebo controlled trial. N Engl J Med 1987, 317:185-191.
130. Creagh-Kirk T, Doi P, Andrews E, et al.: Survival experience among patients with AIDS receiving zidovudine follow-up of patients in a compassionate plea program. JAMA 1988, 260:3009-3015.
131. Lundgren JD, Phillips AN, Pedersen C, et al.: Comparison of long term prognosis of patients wth AIDS treated and not treated with zidovudine. JAMA 1994, 271:1088-1092.
132. Volderbing PA, Lagakos SW, Grimes JM, et al.: The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS clinical trial group. JAMA 1994, 272:437-442.
133. Ioannidis JPA, Cappelleri JC, Lau J, et al.: Early or deferred zidovudine therapy in HIV-infected patients without an AIDS defining illness. Ann Intern Med 1995, 122:856-866.
134. Moore RD, Chaisson RF, Hidalgo J: The efficacy of zidovudine is time limited [letter]. JAMA 1994, 272:1001.
135. Berman DS, Wenglin BD: The efficacy of zidovudine is time limited [letter]. JAMA 1994, 272:1001.
136. Richman DD. Resistance, dug failure and disease progression (review). AIDS Res Hum Retroviruses 1994, 10:901-905
137. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC: A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long term zidovudine recipients. J Infect Dis 1993, 167:526-532.
138. McLeod GX, Hammer SM: Zidovudine: five years later. Ann Intern Med 1992, 117:487-501.
139. Dournon F, Matheron S, Rozenbaum W, et al.: Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 1988, ii:1297-1.502.
140. Concorde Coordinating Committee: Concorde: MRC/ANRS randomised double blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343:871-881.
141. Hamilton JD, Hartigan PH, Simberkoff MS, et al.: A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affair Cooperative Study. N Engl J Med 1992, 326:437-443.
142. Yarchoan R, Mitsuya H, Thomas RV, et al.: In vivo activity against HIV and favourable toxicity profile of 2′,3′-dideoxyinosine. Science 1989, 245:412-415.
143. Cooley TP, Kunches LM, Saunders CA, et al.: Once daily administration of 2′,3′-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS related complex: results of a phase 1 trial. N Engl J Med 1990, 322:1340-1345.
144. Lambert JS, Seidlin M, Reichman RC, et al.: 2′,3′-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or the AIDS-related complex : a phase 1 trial. N Engl J Med 1990, 322:1333-1340.
145. Schooley RT, Cooper D, Moore MD, McKinns R, Rooney JF: Initial combination therapy with ZDV+ddl or ZDC+ddC vs ZDV. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February, 1996 [abstract 202].
146. Thompson M, Creagh T, Harmon M, Rimland D, Lennox J, Stetler H: Impact on survival of combination or sequential antiretroviral therapy compared with AZT monotherapy. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February, 1996 [abstract 284].
147. Hammer SM, Katzenstein DM, Hughes MD, Hirsch MS, Merigan TC for the ACTC 175 Virology Substudy Team:Virological markers and outcome in ACTG 175. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February, 1996 [abstract S24].
148. Gazzard B: Further results from European/Australian Delta trial. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February, 1996 [abstract LB5a].
149. Saravolatz L, Collins G, Hodges J, Winslow D, the Terry Beirn Community Programme for Clinical Research on AIDS 007 Protocol Team: A randomised comparative trial of ZDV versus ZDV plus ddl versus ZDV plus ddC in persons with CD4 cell counts of < 200/mm3. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February, 1996 [abstract LB4].
150. Abranis DI, Goldan AI, Launer C, et al.: A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994, 330:657-662.
151. Cooper DA, Pehrson PO, Pedersen C, et al.: The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double blind randomized trial. AIDS 1993, 7:197-207.
152. Stein DS, Graham NMH, Park LP: The effect of interaction of acyclovir with zidovudine on the progression to AIDS and survival. Analysis of data in the Multicentre AIDS Cohort Study. Ann Intern Med 1994, 121:100-108.
153. Youle MS, Gazzard BG, Johnson MA, et al.: Effect of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. AIDS 1994, 8:641-649.
154. Cameron B, Chiozzi-Heath M, Kravcik S, et al.: Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with Ritonavir. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February, 1996 [abstract LB6a].
155. Lafferty WE, Glidden D, Hopkins S: Survival trends of people with AIDS in Washington state. Am J Public Health 1991, 81:215-218.
156. Dorrell L, Snow MH, Ong EL: Mortality and survival trends in patients with AIDS in North East England from 1984-1992. J Infect 1995, 30:23-27.
157. Fischl MA, Richmann DD, Causey DM, et al.: Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 1989, 262:2405-2410.
158. Chaisson RE, Keruly J, Richman DD, Moore RD: Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. Arch Intern Med 1992, 152:2009-2013.
159. Graham NMH, Zeger SL, Park LP, et al.: The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992, 326:1037-1042.
160. Selik RM, Starcher ET, Curran JW: Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1987, 1:175-182.
161. Delmas MC, Schwoebel V, Heisterkamp SH, et al.: Recent trends in Pneumocystis carinii pneumonia as AIDS defining disease in nine European countries. J Acquir Immune Defic Syndr 1995, 9:74-80.
162. Centers for Disease Control: Revision of the CDC surveillance case definition for the acquired immunodeficiency syndrome. MMWR 1987, 36:3S-15S.
163. Centers for Disease Control: 1993 revised classification system for HIV infection and expanded case definition for AIDS among adolescents and adults. MMWR 1992, 41:RR-17.
164. Bennet CL, Garfinkle JB, Greenfield S, et al.: The relation between hospital experience and in-hospital mortality for patients with AIDS-related PCP. JAMA 1989, 261:2975-2979.
165. Lundgren JD, Melbye M, Pederson C, et al.: Changing patterns of Kaposi's sarcoma in Danish acquired immunodeficiency syndrome patients with complete follow-up. Am J Epidemiol 1995, 141:652-658.
166. Girard PM, Landman R, Gaudebout C, et al.: Prevention of Pneumocystis carinii pneumonia relapse by pentamadine aerosol in zidovudine treated AIDS patients. Lancet 1989, i:1348-1353.
167. Fischl MA, Dickinson GM, La Voie L: Safety and efficacy of sulfamethoxazole and trimethorprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988, 259:1185-1189.
168. Hirschel B, Lazzarin A, Chopard P, et al.: A controlled study of inhaled pentamadine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991, 324:1079-1083.